
A January 2026 review in the Journal of Translational Medicine studied whether or not injectable Wharton’s jelly products contain the living stem cells that some clinics describe. The researchers tested commercial samples and reported that, for the products they examined, most Wharton's jelly contained very few stem cells. For patients who paid thousands of dollars, that finding raises legal questions.
Contact our consumer protection lawyers to weigh your legal options. We are investigating a wide range of stem cell fraud and deceptive marketing claims nationwide.
Wharton’s jelly is the soft, gel-like tissue inside the umbilical cord. It contains collagen, hyaluronic acid and other structural material. It also holds mesenchymal stem cells, though in small amounts. Companies process donated cord tissue into injectable products called allografts and sell them to clinics, which often promote them to patients as stem cell treatments.
The research team referenced above concluded that these products should be viewed as structural tissue preparations rather than cell-based therapies. That finding covers only the products tested, so ask any clinic for the product name and written documentation of what it contains before you pay.
The authors of the 2026 review thawed six commercial products from different vendors and counted the cells in two separate laboratories. They also ran flow cytometry, a test that looks for stem cell markers, and examined samples under a microscope. The results included:
According to the review, published research points to doses of at least 10 million stem cells for local injections and 70 million to 190 million for infusions. The authors described the viable cell counts they found as orders of magnitude below an effective dose. Their conclusion was that these products should be viewed as structural tissue preparations, not cell therapies.
The review has limits and not every clinic uses the same materials. The team tested six products, so the results cannot speak for every vendor or clinic. Patients should treat the study as serious evidence worth investigating, not as a verdict on any named company.
Many Wharton’s jelly products reach clinics under FDA rules for human cells and tissues. That pathway generally depends on minimal manipulation and homologous use, meaning the product performs the same basic job as the original tissue, such as cushioning or structural support. The study notes that using these products for unrelated goals, such as immune system treatment or heart repair, would fall outside that role.
Consumer protection claims often turn on what the patient heard and read. A clinic that promises live stem cells and then injects mostly structural tissue may face allegations of false advertising, fraudulent concealment, unfair and deceptive practices or breach of warranty. Each case depends on the product, the statements made and the law of the state where the treatment took place.
These cases demand a lawyer who understands both consumer fraud and medical product claims. Over 23 years, attorney Joseph Lyon has represented clients in consumer class actions and mass torts across all fifty states.
Did a clinic tell you an injection contained living stem cells? You may have a claim if the clinic made false or misleading statements about what the product contained or what it would do for you.
Claims in these cases can include false advertising, fraudulent concealment, unfair and deceptive practices and breach of warranty. Whether a case succeeds depends on what you were told, what you paid, what was injected and the laws of your state. Time limits also apply and vary by state, so speaking with an attorney early helps protect your options.
Call The Lyon Firm at (513) 381-2333 or request a free, confidential case review. Our team will review your records and explain your options.
Taking the first step doesn’t have to be complicated. In just a few minutes, you can share the basics of your case, and our team will guide you from there: